Webdisclosure.com

Search

ORPHAN SYNERGY EUROPE-PHARMA (EPA:OSE) OSE Immunotherapeutics and Boehringer Ingelheim expand collaboration to develop first-in-class treatments for cancer and cardio-renal-metabolic diseases

Directive transparence : information réglementée

22/05/2024 07:30